3050-5976

Blood Immunology & Cellular Therapy

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 71 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact71 DOIs
2

Deposit reference lists for 9 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact9 DOIs
3

Attach ORCID iDs across 4 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact4 DOIs

DOIs for this ISSN

Showing the top 5 of 71 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 In vivo generation of CAR T cells: biology, delivery platfor… (10.1016/j.bict.2025.100027)
Abstract ORCID
34.95 4
2 CAR-NK cell therapy in acute myeloid leukemia: safer, smarte… (10.1016/j.bict.2025.100030)
Abstract ORCID
23.86 2
3 Talquetamab in heavily pretreated patients with multiple mye… (10.1016/j.bict.2025.100001)
Abstract
22.58 7
4 Comprehensive profiling of AML and T-cell states across dise… (10.1016/j.bict.2025.100004)
Abstract
17.47 4
5 Low-dose nivolumab and lenalidomide in relapsed/refractory H… (10.1016/j.bict.2025.100011)
Abstract
17.47 4
6 Access and outcomes of racial and ethnic minority population… (10.1016/j.bict.2025.100007)
Abstract
15.05 3
7 Impact of body mass index on anti-BCMA chimeric antigen rece… (10.1016/j.bict.2025.100015)
Abstract
11.93 2
8 Broadening CAR-T access: lessons from real-world implementat… (10.1016/j.bict.2025.100026)
Abstract
11.93 2
9 Combining antigen-specific T cells with T-cell engager thera… (10.1016/j.bict.2025.100002)
Abstract
7.53 1
10 Early ICANS recognition with a novel electroencephalogram-ba… (10.1016/j.bict.2025.100006)
Abstract
7.53 1
11 Late effects following CAR T cells and HCT in children and y… (10.1016/j.bict.2025.100008)
Abstract
7.53 1
12 Lipid nanoparticle Fas gene therapy suppresses autoimmune ly… (10.1016/j.bict.2025.100010)
Abstract
7.53 1
13 Streptavidin-drug conjugates streamline optimization of anti… (10.1016/j.bict.2025.100012)
Abstract
7.53 1
14 Donor lymphocyte infusions after HCT are associated with low… (10.1016/j.bict.2025.100016)
Abstract
7.53 1
15 Engineering optimal CAR constructs for allogeneic mesothelin… (10.1016/j.bict.2025.100025)
Abstract
7.53 1
16 Real-world toxicity of brexucabtagene autoleucel in adults w… (10.1016/j.bict.2025.100028)
Abstract
7.53 1
17 Adenosine signaling promotes double-negative T-cell anticanc… (10.1016/j.bict.2026.100031)
Abstract
7.53 1
18 Disarming the natural killers: mechanisms of NK cell dysfunc… (10.1016/j.bict.2026.100038)
Abstract
7.53 1
19 Graft-versus-host disease after chimeric antigen receptor T-… (10.1016/j.bict.2026.100047)
Abstract
7.53 1
20 Brexucabtagene autoleucel consolidation in adult B-cell acut… (10.1016/j.bict.2026.100059)
Abstract
7.53 1
21 Welcome to Blood Immunology & Cellular Therapy (10.1016/j.bict.2025.100003)
Abstract References ORCID
0.00 0
22 Practical use of talquetamab in relapsed/refractory multiple… (10.1016/j.bict.2025.100005)
Abstract
0.00 0
23 Selinexor-based treatments are associated with increased exp… (10.1016/j.bict.2025.100009)
Abstract
0.00 0
24 Delay in CAR-T from single-case agreements: real-world impac… (10.1016/j.bict.2025.100013)
Abstract
0.00 0
25 Modeling Vγ9Vδ2 T-cell exhaustion in vitro: phenotypic and f… (10.1016/j.bict.2025.100014)
Abstract
0.00 0
26 Integrin α4 and CCR5 direct IFN-γ–activated MSCs to the gut… (10.1016/j.bict.2025.100017)
Abstract
0.00 0
27 Utility of neurotoxicity investigations in CD19 and BCMA CAR… (10.1016/j.bict.2025.100018)
Abstract
0.00 0
28 Viral vector-free generation of orthogonal IL-2–responsive C… (10.1016/j.bict.2025.100019)
Abstract
0.00 0
29 Predicting infection risk following CAR-T using the bedside… (10.1016/j.bict.2025.100020)
Abstract
0.00 0
30 Statin therapy with CD19-directed CAR-T therapy improves out… (10.1016/j.bict.2025.100021)
Abstract
0.00 0
31 Nivolumab following CAR-T failure in multiple myeloma and no… (10.1016/j.bict.2025.100022)
Abstract
0.00 0
32 Advancing ATMPs for orphan diseases: redefining the roles of… (10.1016/j.bict.2025.100023)
Abstract
0.00 0
33 Varnimcabtagene autoleucel in relapsed or refractory B-cell… (10.1016/j.bict.2025.100024)
Abstract
0.00 0
34 Tipping the scale: rethinking obesity for CAR T cells in MM (10.1016/j.bict.2025.100029)
Abstract
0.00 0
35 Nonrelapse mortality after CAR T-cell therapy in large B-cel… (10.1016/j.bict.2026.100032)
Abstract
0.00 0
36 CAR T-cell therapy outcomes in plasma cell leukemia (10.1016/j.bict.2026.100033)
Abstract
0.00 0
37 Modakafusp alfa boosts antimyeloma activity via CD38-targeti… (10.1016/j.bict.2026.100034)
Abstract
0.00 0
38 Identification of a plasma immune marker panel for early det… (10.1016/j.bict.2026.100035)
Abstract
0.00 0
39 Preapheresis clinical patient profiles predict patient’s man… (10.1016/j.bict.2026.100036)
Abstract
0.00 0
40 Older patients with LBCL show comparable outcomes to younger… (10.1016/j.bict.2026.100037)
Abstract
0.00 0
41 Adoptive transfer of regulatory T cells in pediatric patient… (10.1016/j.bict.2026.100039)
Abstract
0.00 0
42 Infections following CAR T-cell therapies in children, adole… (10.1016/j.bict.2026.100040)
Abstract
0.00 0
43 CD20×CD3 bispecific antibodies as bridging to CAR-T in aggre… (10.1016/j.bict.2026.100041)
Abstract
0.00 0
44 Identification of an optimal absolute lymphocyte count at le… (10.1016/j.bict.2026.100042)
Abstract
0.00 0
45 Tabelecleucel as a bridge to hematopoietic stem cell transpl… (10.1016/j.bict.2026.100043)
Abstract
0.00 0
46 Systemic steroid treatment of grade I acute GVHD increases s… (10.1016/j.bict.2026.100044)
Abstract
0.00 0
47 Dosing patterns for talquetamab, including dose deescalation… (10.1016/j.bict.2026.100045)
Abstract
0.00 0
48 Plasma proteomics and single-cell RNA-seq identify cellular… (10.1016/j.bict.2026.100046)
Abstract
0.00 0
49 Clinical-grade armored BCMA CAR T cells overcome TGF-β–media… (10.1016/j.bict.2026.100048)
Abstract
0.00 0
50 Lisocabtagene maraleucel outcome in large B-cell lymphoma as… (10.1016/j.bict.2026.100049)
Abstract
0.00 0